FDA scientists opposed the Trump administration’s effort to ease peptides access
Food and Drug Administration scientific staff members opposed an administration effort to ease access to unproven peptide drugs, according to six people familiar with the development. The policy, favored by Health Secretary Robert F. Kennedy Jr., allows for the compounding of certain unapproved peptides, including products like BPC-157 and TB-500. Sources indicated that FDA scientific personnel had limited input in drafting the policy before the Department of Health and Human Services moved forward to permit the broader availability of these substances.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Food and Drug Administration scientists opposed the Trump administration's effort to ease access to unproven peptide drugs.
- ✓ Health Secretary Robert F. Kennedy Jr. favored the plan to provide easier access to unproven peptide drugs.
- ✓ FDA scientific staff members had limited input in drafting the policy, according to six people familiar with its development.
- ✓ The Trump administration acted to clear the way for the production of peptides like BPC-157 and TB-500.
What changed
The Health and Human Services department moved to allow compounding for certain unapproved peptides despite internal scientific opposition.
Live updates
-
FDA Scientists Opposed Trump Peptide Access Plan
Food and Drug Administration scientific staff members opposed an administration effort to ease access to unproven peptide drugs, according to six people familiar with the development. The policy, favored by Health Secretary Robert F. Kennedy Jr., allows for the compounding of certain unapproved peptides, including products like BPC-157 and TB-500. Sources indicated that FDA scientific personnel had limited input in drafting the policy before the Department of Health and Human Services moved forward to permit the broader availability of these substances.
Why it matters
The disagreement highlights internal friction between political leadership and career scientists regarding regulatory standards for unapproved treatments. The administration's shortcut aims to widen availability for specific peptides that have gained popularity despite lacking formal agency clearance. This regulatory shift raises questions about drug safety oversight and the extent of scientific input in federal health decisions.
What is confirmed
- Food and Drug Administration scientists opposed the Trump administration's effort to ease access to unproven peptide drugs.
- Health Secretary Robert F. Kennedy Jr. favored the plan to provide easier access to unproven peptide drugs.
- FDA scientific staff members had limited input in drafting the policy, according to six people familiar with its development.
- The Trump administration acted to clear the way for the production of peptides like BPC-157 and TB-500.
What to watch next
- Further official guidance or safety warnings from FDA scientists regarding specific compounded peptides
- Response from lawmakers or health committees regarding the use of administrative shortcuts for unapproved drugs
confidence 100%Sources used for this update (16)
- www.newsday.com — Newsday | Long Island's & NYC's News Source - Newsday
- www.click2houston.com — Click2Houston | Houston News, Texas News, Weather, Sports | KPRC ...
- abcnews.com — ABC News - Breaking News, Latest News and Videos
- www.clickorlando.com — ClickOrlando l Orlando, Florida News, Local Headlines l WKMG News...
- www.breitbart.com — Israel / Middle East - Latest News
- www.news4jax.com — US stocks hold steady as the countdown ticks to a Federal Reserve decision on interest rates
- AP News — FDA scientists opposed the Trump administration’s effort to ease peptides access
- NBC News — RFK Jr. takes shortcut to make some peptides more widely available
- STAT — HHS moves to allow compounding of some unapproved peptides
- CNBC — Fact vs. fiction: Doctors share whether peptides are safe and effective
- MarketWatch — Trump administration clears the way for production of peptides like BPC-157 and TB-500
- www.thestar.com — Jamal Shead delivers in Raptors’ blowout win
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community